The purpose of this invention is to maximize the efficacy of, minimize the incidence of adverse effects from, and improve the storage stability of eye drops that contain: a peptide (SSSR), the amino acid sequence of which is represented by Ser-Ser-Ser-Arg, or a pharmacologically-permitted salt thereof； and a peptide (FGLM), the amino acid sequence of which is represented by Phe-Gly-Leu-Met-NH, or a pharmacologically-permitted salt thereof. The concentration ratio between the SSSR or pharmacologically-permitted salt thereof and the FGLM or pharmacologically-permitted salt thereof is between 1/15 and 1/50. The concentration of the SSSR or pharmacologically-permitted salt thereof is between 0.001% and 0.3% (w/v) and the concentration of the FGLM or pharmacologically-permitted salt thereof is between 0.015% and 1.5% (w/v). The pH of the eye drops is maintained between 2.5 and 6.5.
